期刊
TRANSBOUNDARY AND EMERGING DISEASES
卷 69, 期 4, 页码 E254-E266出版社
WILEY-HINDAWI
DOI: 10.1111/tbed.14292
关键词
bivalent vaccine; Echinococcus granulosus; EG95 protein; rabies virus
资金
- National Key Research and Development Program of China [2019YFC1200500]
- National Nature Science Foundation of China [31902308]
- Shandong Provincial Natural Science Foundation [ZR2019QC010]
- Shandong Key Research and Development Program [2019GNC106006]
A bivalent vaccine targeting cystic echinococcosis (CE) and rabies, generated in this study, showed promising results in protecting sheep and cattle in endemic areas against both diseases. This vaccine induced robust immune responses and provided high levels of protection in animal models.
Cystic echinococcosis (CE), caused by Echinococcus granulosus (E, is a zoonosis with a worldwide distribution, resulting in heavy impact to public health and social economics. In this study, we generated a recombinant rabies virus (RABV) expressing EG95 protein of E. granulosus (LBNSE-EG95) as a bivalent candidate vaccine for use in sheep and cattle against CE and rabies, which is another severe health threat in CE-endemic areas. It was found that EG95 was successfully expressed without altering the pathogenicity of parent LBNSE vector. Further study showed that LBNSE-EG95 immunization in mice elicited activation of dendric cells (DCs) and B cells and induced Th1-/Th2-mediated cellular immune responses, leading to robust production of RABV neutralizing antibodies and high level of EG95-sepecific antibodies with more than 90% protection against CE. In addition, single dose of LBNSE-EG95 conferred full protection against lethal RABV challenge in mice. Collectively, these results suggest that the recombinant LBNSE-EG95 has the potential to be developed as an efficient bivalent vaccine for sheep and cattle use in endemic areas of CE and rabies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据